Ocumension Therapeutics
01477
Company Profile
Business description
Ocumension Therapeutics is an ophthalmic pharmaceutical platform company identifying, developing, and commercializing ophthalmic therapies. It provides a pharmaceutical total solution to address unmet ophthalmic medical needs in China. Its product candidates include OT-401 (YUTIQ), OT-101, OT-301 (NCX 470), OT-1001 (ZERVIATE), OT-502 (DEXYCU), OT-202, OT-503 (NCX 4251), OT-701, Ou Qin, Brimonidine tartrate eye drop, 0.5% moxifloxacin eye drop, OT-601-C, OT-302, OT-1301, T-1601, and OT-1602.
Contact
No. 1858 Yinzhongnan Road
Guoxiang Subdistrict
Wuzhong District
SuzhouJiangsu
CHNT: +86 2161493800
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
477
Stocks News & Analysis
stocks
2 undervalued ASX shares report
These two ASX shares are trading at a discount to our fair value.
stocks
Turmoil at WiseTech
Board members step down over differences on the role of former CEO Richard White.
video
What does the RBA rate cut mean for investors?
Morningstar's Chief Investment Officer for Asia-Pacific and Director of Personal Finance share their thoughts on the recent RBA rate cut.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,494.50 | 65.60 | -0.77% |
| CAC 40 | 8,090.99 | 63.52 | -0.78% |
| DAX 40 | 22,425.93 | 138.37 | 0.62% |
| Dow JONES (US) | 43,461.21 | 33.19 | 0.08% |
| FTSE 100 | 8,658.98 | 0.39 | -0.00% |
| HKSE | 22,998.69 | 342.92 | -1.47% |
| NASDAQ | 19,286.93 | 237.08 | -1.21% |
| Nikkei 225 | 38,345.99 | 430.95 | -1.11% |
| NZX 50 Index | 12,355.74 | 175.98 | -1.40% |
| S&P 500 | 5,983.25 | 29.88 | -0.50% |
| S&P/ASX 200 | 8,247.00 | 61.20 | -0.74% |
| SSE Composite Index | 3,359.27 | 13.76 | -0.41% |